Pgi34 - A Cost Saving Measure From the Utilisation of Biosimilar Infliximab in the Irish Secondary Care Setting
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.876
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV